Publications by authors named "Jeanenne Nelson"

Claim this Profile
R
Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma.
Amanda S Bruno, Jenny L Willson, Joanna M Opalinska, Jeanenne J Nelson, Orsolya E Lunacsek

Expert Rev Hematol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients.
Nicole G Chau, Clement Ma, Kristina Danga, Hasan Al-Sayegh, Valentina Nardi, Jeanenne J Nelson

JNCI Cancer Spectr· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prescriber Compliance With Liver Monitoring Guidelines for Pazopanib in the Postapproval Setting: Results From a Distributed Research Network.
Sumitra Shantakumar, Beth L Nordstrom, Susan A Hall, Luc Djousse, Myrthe P P van Herk-Sukel, Jeanenne J Nelson

J Patient Saf· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.
Sumitra Shantakumar, Beth L Nordstrom, Luc Djousse, Susan A Hall, David R Gagnon, Jeanenne Nelson

Cancer Chemother Pharmacol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The occurrence of non-melanoma malignant skin lesions and non-cutaneous squamous-cell carcinoma among metastatic melanoma patients: an observational cohort study in Denmark.
Haojie Li, Lars Pedersen, Mette Nørgaard, Sinna P Ulrichsen, Sandra K Thygesen, Jeanenne J Nelson

BMC Cancer· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data.
Daniel Parks, Xiwu Lin, Jeffery L Painter, Jie Cheng, Christine M Hunt, Jeanenne J Nelson

Pharmacoepidemiol Drug Saf· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disruptions in Liver Function among Cancer Patients and Patients Treated with Tyrosine Kinase Inhibiting Drugs: Comparisons of Two Population-Based Databases.
Sarah H Landis, Beth L Nordstrom, Leah B Sansbury, Sumitra Shantakumar, Samantha A St Laurent, Jeanenne J Nelson

J Cancer Epidemiol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comorbidities and Concomitant Medication Use in Men with Prostate Cancer or High Levels of PSA Compared to Matched Controls: A GPRD Analysis.
Haojie Li, Elizabeth Hodgson, Louise Watson, Amit Shukla, Jeanenne J Nelson

J Cancer Epidemiol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular events in cancer patients treated with highly or moderately emetogenic chemotherapy: results from a population-based study.
Thao T Vo, Jeanenne J Nelson

J Cancer Epidemiol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies.
Harald Grallert, Josée Dupuis, Joshua C Bis, Abbas Dehghan, Maja Barbalic, Jeanenne J Nelson

Eur Heart J· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoprotein-associated phospholipase A2 activity improves risk discrimination of incident coronary heart disease among women.
Ida J Hatoum, Nancy R Cook, Jeanenne J Nelson, Kathryn M Rexrode, Eric B Rimm

Am Heart J· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoprotein-associated phospholipase A(2), inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
Muriel J Caslake, Chris J Packard, Michele Robertson, Josephine Cooney, Jeanenne J Nelson

Atherosclerosis· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes.
Ida J Hatoum, Frank B Hu, Jeanenne J Nelson, Eric B Rimm

Diabetes· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study.
Nancy Swords Jenny, Cam Solomon, Mary Cushman, Russell P Tracy, Jeanenne J Nelson

Atherosclerosis· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease.
Ida J Hatoum, Jeanenne J Nelson, Nancy R Cook, Frank B Hu, Eric B Rimm

Am J Clin Nutr· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study.
Takeki Suzuki, Cam Solomon, Nancy Swords Jenny, Russell Tracy, Jeanenne J Nelson

Circ Heart Fail· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malmö, Sweden.
Margaretha Persson, Göran Berglund, Jeanenne J Nelson, Bo Hedblad

Atherosclerosis· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
Sander J Robins, Dorothea Collins, Jeanenne J Nelson, Hanna E Bloomfield, Bela F Asztalos

Arterioscler Thromb Vasc Biol· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study.
Curt D Furberg, Jeanenne J Nelson, Cam Solomon, Mary Cushman, Nancy Swords Jenny

J Am Geriatr Soc· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The association between lipoprotein-associated phospholipase A2 and cardiovascular disease and total mortality in vascular medicine patients.
Matthew A Allison, Julie O Denenberg, Jeanenne J Nelson, Loki Natarajan, Michael H Criqui

J Vasc Surg· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects.
Margaretha Persson, Bo Hedblad, Jeanenne J Nelson, Göran Berglund

Arterioscler Thromb Vasc Biol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beta-blocker dosing in community-based treatment of heart failure.
Michael B Fowler, Sandra R Lottes, Jeanenne J Nelson, Mary Ann Lukas, Edward M Gilbert

Am Heart J· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice.
Barry M Massie, Jeanenne J Nelson, Mary Ann Lukas, Barry Greenberg, Michael B Fowler

Am J Cardiol· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability, safety, and efficacy of beta-blockade in black patients with heart failure in the community setting: insights from a large prospective beta-blocker registry.
William T Abraham, Barry M Massie, Mary Ann Lukas, Sandra R Lottes, Jeanenne J Nelson

Congest Heart Fail· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The association of the ankle-brachial index with incident coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study, 1987-2001.
Beth D Weatherley, Jeanenne J Nelson, Gerardo Heiss, Lloyd E Chambless, A Richey Sharrett

BMC Cardiovasc Disord· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis